genprowebdirectory
GEN Edge
Featured News
Multimedia
News
Insights
Trends for 2020
Trends for 2021
Trends for 2023
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
GEN Edge
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Videos
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Drug Discovery
Brain Cell Signaling Linked to Yo-Yo Effect of Dieting
Liquid Biopsies
Illumina, Icahn Spar over Board Indemnification for Grail Purchase
Cancer
Cancer Diagnosis and Treatment Could Be Affected by Circadian Rhythm
Antibodies
Blood Clotting Finding May Lead to New Approach to Improve Hemostasis
Gastrointestinal Disorders
Intracellular Sensor May Lead to Novel Skin and Intestinal Therapies
Insights
All
Trends for 2020
Trends for 2021
Trends for 2023
AgBio
Plants to Play Larger Role in Battle against COVID-19
Bioprocessing
Merck Biomanufacturing Optimization Sees Major Production Gains
Bioprocessing
Pharmaceutical Manufacturers Need to Stay Focused on Supply Chain Audit
Bioprocessing
Cell-Free Synthesis of Peptidomimetic Drugs by International Research Team
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
GEN Edge
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Drug Discovery
Seven Biopharma Trends to Watch in 2023
A-Lists
Top 50 NIH-Funded Institutions of 2022
A-Lists
Top 10 U.S. Biopharma Clusters
A-Lists
Top 10 Spatial Biology Companies
A-Lists
Top 25 Biotech Companies of 2022
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Videos
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
Antibodies
Antibody Drug Conjugates
Antibody Drug Conjugates
Antibody Drug Conjugates
Bispecific Antibodies
Epitope Mapping
Monoclonal Antibodies
Random
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Antibody Drug Conjugates
Millennium Taps Seattle Genetics for Antibody-Drug Conjugate Development with $4M Up Front
Antibody Drug Conjugates
Innova Licenses Antibodies to Develop Cancer Research Tools
Antibody Drug Conjugates
Medarex Taps Lonza for Biomanufacturing
Antibody Drug Conjugates
Amgen to Apply ImmunoGen TAP Technology to Another Cancer Target
Antibody Drug Conjugates
Genentech Ends Collaboration with Seattle Genetics for Phase I Anticancer mAb
Antibody Drug Conjugates
Millennium Gains Seattle’s Late-Stage Lymphoma Drug with Initial $60M Fee
Antibody Drug Conjugates
Seattle Genetics Receives $12M Up Front in Deal with GSK
Antibody Drug Conjugates
Seattle Genetics Gains $12M from Genentech with Expanded ADC Partnership
Antibody Drug Conjugates
Disappointing Phase II Data Leads Seattle to Ditch AML Candidate
Antibody Drug Conjugates
Genmab Taps into Seattle’s ADC Technology to Develop Anticancer HuMax-TF Conjugate
Antibody Drug Conjugates
Seattle and Millennium Report 75% Response Rate in Pivotal ADC Hodgkin...
Antibody Drug Conjugates
Ambrx and Fabrus Ink Antibody-Drug Conjugate Collaboration
Antibody Drug Conjugates
Genentech and Pfizer Join the Antibody-Drug Conjugate Bandwagon
Antibody Drug Conjugates
Abbott to Use Seattle Genetics’ Antibody-Drug Conjugate Platform for $8M Up...
Antibody Drug Conjugates
Seattle and Genmab Sign Antibody-Drug Conjugate Agreement in Cancer
1
2
3
...
12
Page 1 of 12
Scroll Up
![Firm will now focus on pivotal Hodgkin lymphoma ADC and earlier clinical pipeline. [© GodMaker - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/Sept13_2010_22822004_OldLadywCat_SeatlleDitchesAMLCandidate6126023610-324x160.jpg "Disappointing Phase II Data Leads Seattle to Ditch AML Candidate")
![Brentuximab vedotin on track for BLA filing with FDA during first half of 2011. [© Sebastian Kaulitzki - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/Sept27_2010_3398153_AntibodiesRWBCs_SeattleMilleniumPositiveHodgkinLymphomaTrialResults2191353123-324x160.jpg "Seattle and Millennium Report 75% Response Rate in Pivotal ADC Hodgkin Lymphoma Trial")
![Genentech will tap Spirogen’s technology and Pfizer will use Seattle Genetics’.[Sebastian Kaulitzki-Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/UGENWebsitepicturesTopStoriesJan2011Jan6_2011_8300503_AntibodiesBlood_BIandMacroGenicsAntibodyDeal1727281211-324x160.jpg "Genentech and Pfizer Join the Antibody-Drug Conjugate Bandwagon")
![Milestone fees due to Seattle Genetics could total $200 million.[Markus Schnatmann-Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/March22_2011_15327090_GreenWhiteAntibodyAttachingtoAntigens_SeatlleADCcollabAbbott1409924912-324x160.jpg "Abbott to Use Seattle Genetics’ Antibody-Drug Conjugate Platform for $8M Up Front")
![Seattle retains option to co-develop resulting anticancer candidates at end of Phase I development.[Sebastian Kaulitzki-Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/April19_2011_8300503_AntibodiesBlood_SeatlleGenmabADCcollab9314732222-324x160.jpg "Seattle and Genmab Sign Antibody-Drug Conjugate Agreement in Cancer")